

ANNUAL 180°N CONFERENCE

PoMo/Nye Hjorten Teater, Trondheim, April 28-29 2026

TUESDAY APRIL 28

- 11:30-12:00 Registration, refreshments and mingling
12:00-12:10 Opening by Trond Mohn
12:10-12:20 Welcome – Tone Bathen and Live Eikenes
12:20-13:00 Keynote lecture:
Professor Thomas Hope (UCSF) – PSMA-targeted imaging and therapy in prostate cancer

13:00-14:00 Lunch at Olgas

Session 1 Diagnostic and treatment advances in cancer and dementia

- 14:00-14:15 FAPI PET/MRI in breast cancer - Håkon Johansen
14:15-14:30 PET/MRI in prostate cancer – Ingerid Skjei Knudtsen
14:30-14:45 Advancing diagnostics and treatment of prostate cancer using dynamic PET – Elin Kile
14:45-15:00 Immuno-PET and lung cancer - Inigo Martinez
15:00-15:15 PET/MRI imaging as a biomarker of amyloid- β , tau, and hypometabolism: towards improving diagnosis and classification for treatment eligibility in dementia - Vere Megens and Ebba Muller
15:15-16:00 Coffee break and mingling

Session 2 PET tracers and optimization

- 16:00 - 16:30 Establishing a high-throughput Radiopharmacy Ecosystem: Presenting KFSC&RC as a regional model in radiopharmaceutical production - Waqas Rafique
16:30 - 16:45 In-house sterility testing – Validation of BactAlert for the testing of Radiopharmaceuticals – Ole Heine Kvernes
16:45 - 17:00 Investigating fluorination of silicon-oxygen bonds – Frida Johanne Rakneberg Lundevall
17:00 - 17:15 Drug loaded neutrophil targeted nanocarriers and breast cancer - Elena Markova

19.00 - 22.00 Conference dinner at Rive Gauche

WEDNESDAY APRIL 29

Session 3 External radiotherapy and synergies with PET

- 09:00-09:30 Protontherapy – Friend or foe? – Petter Brandal
09:30-09:50 Personalized treatment through automated PET/MRI-guided adaptive proton therapy - Marte Kåstad Høiskar
09:50-10:10 ProtonSUMMIT – translational proton research in Bergen - Camilla Stokkevåg
10:10-10:30 Coffee break

Session 4 Time with the industry sponsors

- 10.30-11.00 Siemens, Triskem, Bruker and GE

- 11:00-12.00 PoMo guided tour

- 12:15-13.15 Lunch at Olgas

Session 5 Targeted radionuclide therapy

- 13:15-13:30 Radiotheranostics and brain cancer - Mathias Kranz
13:30-13:45 Preclinical development and evaluation of ^{212}Pb and ^{224}Ra based therapeutic radiopharmaceuticals- Asta Juzeniene
13:45-14:00 ^{212}Pb -PSMA clinical trials – Eivor Hernes
14:00-14:15 First experience with intraperitoneal ^{224}Ra -labeled microparticles (Radspherin®) after cytoreductive surgery in patients with peritoneal recurrence of ovarian cancer or colorectal cancer – Mona-Elisabeth Revheim
14:15-14:30 Imaging of alpha emitters – Caroline Stokke
14:30-14:45 Theranostic treatment of glioma - Anna Karlberg
14:45-15:15 Coffee break

Session 6 Future Nuclear Medicine in Norway – Panel discussion

- 15:15-16:30 Chair Tone F. Bathen
Panelists Ole Johan Borge - Forskningsrådet
Oddveig Åsheim - Trond Mohn Foundation
Monica Larsen - Legemiddelindustrien (LMI)
Torggrim Tandstad - Oncologist St. Olavs hospital
Ketil Widerberg - Oslo Cancer Cluster
The panel discussion will be held in Norwegian

- 16:30-17:00 Closing remarks